Table 3. SF-36 scores for 27 patients receiving rituximab induction and maintenance treatment, norm-based and raw scores, at baseline and during follow-up a .
| Follow-up (months) | Baseline | 3 | 6 | 10 | 15 | 20 | 24 | 30 | 36 b |
| Norm-based, mean (SD) | n = 27 | n = 26 | n = 25 | n = 24 | n = 24 | n = 23 | n = 25 | n = 18 | n = 18 |
| Physical health summary | 25.6 (6.6) | 27.2 (6.8) | 32.2 (10.1) | 33.1 (12.1) | 35.7 (12.3) | 37.9 (13.7) | 36.4 (12.7) | 38.6 (15.7) | 38.6 (14.3) |
| Mental health summary | 44.6 (10.4) | 44.1 (9.6) | 47.8 (7.4) | 49.2 (6.6) | 46.1 (9.3) | 49.4 (8.8) | 48.7 (8.3) | 49.3 (9.1) | 47.8 (9.3) |
| Physical Function | 33.0 (7.9) | 34.7 (9.5) | 39.9 (9.4) | 40.7 (11.8) | 42.8 (11.3) | 44.2 (11.5) | 43.4 (11.3) | 43.5 (12.7) | 44.2 (11.3) |
| Role Physical | 29.1 (3.4) | 29.7 (4.2) | 34.0 (9.9) | 33.7 (10.6) | 35.5 (10.0) | 38.3 (12.3) | 36.0 (11.2) | 37.6 (13.6) | 37.6 (12.9) |
| Bodily Pain | 32.0 (8.4) | 33.0 (8.1) | 37.0 (9.0) | 39.0 (11.9) | 39.6 (12.6) | 43.4 (14.0) | 41.6 (11.3) | 42.7 (14.2) | 42.3 (13.3) |
| General Health | 31.1 (5.0) | 31.4 (5.2) | 35.0 (8.5) | 36.3 (9.9) | 36.6 (10.6) | 38.0 (11.7) | 37.7 (10.5) | 42.5 (14.4) | 41.2 (12.9) |
| Vitality | 31.6 (5.9) | 33.1 (7.0) | 40.2 (10.6) | 41.6 (11.7) | 40.9 (13.0) | 44.6 (13.6) | 41.8 (12.0) | 44.5 (15.8) | 41.0 (15.3) |
| Social Function | 21.4 (8.7) | 22.8 (10.0) | 30.5 (12.9) | 31.9 (14.5) | 31.2 (14.9) | 36.5 (14.6) | 35.7 (13.4) | 38.3 (16.5) | 37.7 (16.4) |
| Role Emotional | 48.9 (11.1) | 48.3 (11.1) | 48.8 (11.0) | 49.8 (10.0) | 48.1 (11.1) | 49.6 (10.2) | 49.7 (11.1) | 49.1 (12.2) | 48.0 (13.1) |
| Mental Health | 46.9 (10.7) | 46.1 (10.2) | 50.1 (7.3) | 51.4 (7.8) | 49.9 (9.6) | 51.7 (9.8) | 50.8 (9.2) | 50.6 (8.6) | 50.6 (9.2) |
| Follow-up (months) | Baseline | 3 | 6 | 10 | 15 | 20 | 24 | 30 | 36 |
| Raw scores, mean (SD) | n = 27 | n = 26 | n = 25 | n = 24 | n = 24 | n = 23 | n = 25 | n = 18 | n = 18 |
| Physical Function | 40.6 (19.3) | 44.8 (23.2) | 57.5 (23.0) | 59.6 (29.1) | 64.6 (27.8) | 68.0 (28.2) | 67.1 (27.5) | 66.4 (31.3) | 68.1 (27.8) |
| Role Physical | 4.6 (12.1) | 6.7 (15.1) | 22.0 (34.9) | 20.8 (37.3) | 27.1 (35.3) | 37.0 (43.3) | 31.7 (41.0) | 34.7 (47.9) | 34.7 (45.5) |
| Bodily Pain | 30.0 (20.2) | 32.3 (19.4) | 42.0 (21.8) | 46.9 (28.6) | 48.2 (30.4) | 57.4 (33.7) | 55.0 (34.4) | 55.7 (34.3) | 54.9 (32.2) |
| General Health | 29.8 (10.8) | 30.6 (11.2) | 38.2 (18.4) | 41.1 (21.4) | 41.7 (23.0) | 44.7 (25.3) | 46.3 (24.8) | 54.4 (31.1) | 51.7 (27.8) |
| Vitality | 17.6 (13.0) | 20.8 (15.2) | 36.2 (23.1) | 39.4 (25.5) | 37.7 (28.4) | 45.9 (29.6) | 41.9 (27.8) | 45.6 (34.5) | 38.1 (33.3) |
| Social Function | 20.4 (20.0) | 23.6 (22.7) | 41.0 (29.4) | 44.3 (33.2) | 42.7 (34.0) | 54.9 (33.2) | 54.8 (31.4) | 59.0 (37.6) | 57.6 (37.4) |
| Role Emotional | 79.0 (36.0) | 76.9 (36.2) | 78.7 (35.9) | 81.9 (32.6) | 72.2 (38.9) | 81.1 (33.1) | 84.6 (34.3) | 79.6 (39.8) | 81.5 (38.3) |
| Mental Health | 70.8 (18.5) | 69.5 (17.7) | 76.5 (12.6) | 78.7 (13.4) | 76.0 (16.5) | 79.1 (16.9) | 78.2 (15.8) | 77.3 (14.8) | 76.9 (16.3) |
a:SF-36 (Norwegian ver. 1.2) data during follow-up, for 27 patients receiving rituximab induction and maintenance treatment, including 17 patients with, and 10 without, clinically significant response. SF-36 scores (mean, SD) for Physical health summary score, Mental health summary score, and both norm-based scores (with population mean 50, according to US 1998) and raw scores (scale 0–100) for the subdimensions Physical function, Role physical, Bodily pain, General health, Vitality, Social function, Role emotional, and Mental health, are shown. One pilot patient did not fill in SF-36 forms. Including baseline until 24 months follow-up, 15 out of 189 forms were missing (7.9%). Out of 17 patients with clinically significant responses, one withdrew from study after 24 months due to a diagnosis of T2N0 breast cancer, and two patients withdrew from follow-up after 25 and 32 months, respectively. Out of 10 patients with no clinically significant response, one patient withdrew from study after 12 months, and four patients after 24–26 months follow-up. Thus, the mean SF-36 scores at 30 and 36 months will be influenced by fewer non-responders included in the analyses.
b: in two patients, the last SF-36 forms were completed at 33 and 35 months, respectively.